Compound Biejiaruangan Tablets Combined Nucleoside Drug Treatment Of Hepatitis B Cirrhosis On Serum PDGF-BB Influence And Related Research

Objective To explore the serological diagnostic marker of liver fibrosis,Clearsignificance about platelet-derived growth factor-BB of serum in the diagnosis of liverfibrosis, Explore the Compound Biejiaruangan piece in the anti-liver fibrosis may exist inmechanism of action, And observe the effect of compound Biejiaruangan tablets andnucleoside drug treatment. Methods March2010May to2011in our department (GeneralHospital of Ningxia Medical Disease Division) regularly review the out-patient hepatitis Bpatients with cirrhosis and hospitalization in patients with liver cirrhosis62cases of infection,were randomly divided into two groups (A, B)+nucleoside drugs, anti-virus, group A for thetreatment of31cases, to give compound Biejiaruangan piece, the course of the disease basedon elevated liver aminotransferase levels appropriate to give bicyclol reducing enzymetreatment; group B for the control group31was treated with nucleoside drugs, anti-virus,reducing enzyme treatment bicyclol and other appropriate given the course of the diseasebased on elevated liver transaminase levels. Treatment lasted six months. And to receiveoutpatient healthy persons serum31cases of group C as control group. Observe and recordthe serum of PDGF-BB, and hyaluronic acid (HA), laminin (LN), collagen type IV (IV-C)levels and other indicators before and after treatment.Results Were included for thesubjects of a total of93cases in mind, group A31cases,31cases of Group B, health blankcontrol group of31cases. Serum PDGF-BB and HA, LN, Ⅳ-C change in group A, B, beforeand after treatment were statistically significant differences (P <0.05). Group A serum,PDGF-BB and HA, LN, Ⅳ-C before and after treatment, changes in levels than in group B the level of change is more significant, and there is a significant difference (P <0.05). GroupA and group B the treatment of portal vein and spleen thickness variation than beforetreatment, no significant difference (P>0.05). A and PDGF-BB, B groups62cases ofhepatitis B patients with cirrhosis before treatment serum HA, LN, Ⅳ-C, there is a certaincorrelation (P <0.05).Conclusions (1)serum PDGF-BB plays an important role in theprocess of the formation of liver cirrhosis. Some clinical value in the diagnosis of early livercirrhosis, and to provide an objective basis for future diagnosis of hepatitis B liver fibrosisserum.(2) the compound Biejiaruangan piece anti-hepatic fibrosis mechanisms exist toachieve the biological role of anti-liver fibrosis effect on serum of PDGF-BB levels. Early (3)of compound Biejiaruangan tablets nucleoside antiviral drugs can be effective to improveserum hepatic fibrosis markers, imaging (portal vein diameter and thickness) of the spleenchange requires a long process.